article · 2011
Phase 2 study of nilotinib as third‐line therapy for patients with gastrointestinal stromal tumor
These results suggest that nilotinib is generally well tolerated and has encouraging antitumor activity in patients with GIST who failed both imatinib and su...
85 citationsDOI: https://doi.org/10.1002/cncr.26120Open accessPDF reported by metadata